Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02321423 · ClinicalTrials.gov registry record
International Pachyonychia Congenita Research Registry
A clinical trial of Pachyonychia Congenita, sponsored by Pachyonychia Congenita Project.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT02321423 is a study of Pachyonychia Congenita that is actively recruiting participants, run by Pachyonychia Congenita Project. The registered enrollment target is 2,000 participants, above the 42-participant average among 4 other Pachyonychia Congenita trials with a reported enrollment target (4662% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02321423, a study of Pachyonychia Congenita, is actively recruiting participants, sponsored by Pachyonychia Congenita Project.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
International Pachyonychia Congenita Research Registry (IPCRR) is a patient registry for those suffering from Pachyonychia Congenita (PC). PC is an ultra-rare extremely painful skin disorder that causes painful blisters and callus on feet and sometimes hands, thickened nails, cysts and other features. The IPCRR consists of a questionnaire, patient photos, optional physician notes from telephone consultation to validate questionnaire and free genetic testing.
Conditions Studied
Study Locations (1)
Utah
- Pachyonychia Congenita Project - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2004-04 |
| Est. Completion | 2030-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02321423
The ClinicalTrials.gov registry entry for NCT02321423 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 42-participant average among 4 other Pachyonychia Congenita trials with a reported enrollment target (4662% higher). The listed sponsor is Pachyonychia Congenita Project, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pachyonychia Congenita appearing as the primary indexed condition, and to 0 interventions.
NCT02321423 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT02321423 about?
NCT02321423 is a clinical study titled "International Pachyonychia Congenita Research Registry". International Pachyonychia Congenita Research Registry (IPCRR) is a patient registry for those suffering from Pachyonychia Congenita (PC). PC is an ultra-rare extremely painful skin disorder that causes painful blisters and callus on feet and sometimes hands, thickened nails, cysts and other feature...
What is the current status of trial NCT02321423?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2004-04. Estimated completion is 2030-12.
What conditions does trial NCT02321423 study?
This clinical trial studies the following conditions: Pachyonychia Congenita.
Who is sponsoring clinical trial NCT02321423?
This trial is sponsored by Pachyonychia Congenita Project, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02321423 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pachyonychia Congenita
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
RECRUITING · Phase 3
-
Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
COMPLETED · Phase 1
-
VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
COMPLETED · Phase 3
-
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.